FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

FDA Withdraws Approval of 19 Not Marketed NDAs

Federal Register notice : FDA withdraws approval of 19 NDAs from multiple applicants after they notified the agency that the drugs were no longer mark...

Federal Register

Nipride Not Withdrawn Due to Safety/Efficacy: FDA

Federal Register notice: FDA determines that Exela Pharma Sciences Nipride RTU (sodium nitroprusside), 10mg/50mL, was not withdrawn from sale for safe...

Medical Devices

CDRH Publishes 90 Examples of Real-World Evidence Use

CDRH publishes an analysis of 90 examples of ways in which real-world evidence has been used in regulatory submissions and decisions.

Medical Devices

Stakeholders Question HHS Premarket Notification Plan

Four medical device stakeholders voice objections to a Trump administration HHS plan to declare some medical devices exempt from FDA 510(k) review.

Human Drugs

AbbVie Rinvoq sNDA Review Extended 3 Months

FDA extends by three months its review of an AbbVie supplemental NDA for Rinvoq (upadacitinib) and its use in treating adult patients with active psor...

Medical Devices

Catalyst OrthoScience Shoulder System Cleared

FDA clears a Catalyst OrthoScience 510(k) for its reverse shoulder system.

Human Drugs

Multilateral Working Group on Pharmaceutical Mergers

The Federal Trade Commission says it is joining with several other organizations that regulate competition to update the approach to analyzing pharmac...

Human Drugs

Merck NDA for Belzutifan Accepted for Priority Review

FDA accepts for priority review a Merck NDA for belzutifan for treating patients with von Hippel-Lindau disease-associated renal cell carcinoma that d...

Human Drugs

FY 2020 GDUFA Science and Research Highlights

The CDER Offices of Generic Drugs and Pharmaceutical Quality issue a report on the FY 2020 GDUFA Science and Research Program activities.

Medical Devices

How to Boost Quality System Inspection Success: Consultant

Medical device consultant Adam Atherton offers three recommendations for preparing for an FDA quality system audit.